{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T11:04:11Z","timestamp":1777547051497,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K17564"],"award-info":[{"award-number":["20K17564"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.transproceed.2023.03.037","type":"journal-article","created":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T15:32:23Z","timestamp":1682350343000},"page":"792-796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of Mammalian Target of Rapamycin Inhibition on Activated Regulatory T-Cell Expansion in Kidney Transplantation"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4959-6290","authenticated-orcid":false,"given":"Yusuke","family":"Tomita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeko","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Takiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michio","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2023.03.037_bib0001","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(78)91970-0","article-title":"Cyclosporin A in patients receiving renal allografts from cadaver donors","volume":"2","author":"Calne","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0002","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.trre.2013.04.003","article-title":"The impact of calcineurin inhibitors on graft survival","volume":"27","author":"Rush","year":"2013","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224203","article-title":"Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients","volume":"14","author":"Tomita","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0004","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1016\/j.transproceed.2014.04.018","article-title":"Negative impact of underlying non-insulin-dependent diabetes mellitus nephropathy on long-term allograft survival in kidney transplantation: a 10-year analysis from a single center","volume":"46","author":"Tomita","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0005","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1056\/NEJMoa020009","article-title":"The natural history of chronic allograft nephropathy","volume":"349","author":"Nankivell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0006","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2215\/CJN.04800908","article-title":"Calcineurin inhibitor nephrotoxicity","volume":"4","author":"Naesens","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0007","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s10157-019-01822-6","article-title":"Preventive effect of early introduction of everolimus and reduced-exposure tacrolimus on renal interstitial fibrosis in de novo living-donor renal transplant recipients","volume":"24","author":"Ishida","year":"2020","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0008","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1681\/ASN.2018010009","article-title":"Everolimus with reduced calcineurin inhibitor exposure in renal transplantation","volume":"29","author":"Pascual","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0009","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1111\/ajt.15480","article-title":"Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study","volume":"19","author":"Berger","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0010","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/TP.0000000000002626","article-title":"Safety of everolimus with reduced calcineurin inhibitor exposure in de novo kidney transplants: an analysis from the randomized TRANSFORM study","volume":"103","author":"Tedesco-Silva","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0011","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2019.01.041","article-title":"An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients","volume":"96","author":"Sommerer","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0012","doi-asserted-by":"crossref","first-page":"e14415","DOI":"10.1111\/ctr.14415","article-title":"Everolimus-facilitated calcineurin inhibitor reduction in Asian de novo kidney transplant recipients: 2-year results from the subgroup analysis of the TRANSFORM study","volume":"35","author":"Watarai","year":"2021","journal-title":"Clin Transplant"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0013","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1681\/ASN.2010040351","article-title":"The evolving role of mTOR inhibition in transplantation tolerance","volume":"22","author":"McMahon","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0014","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/cei.12669","article-title":"Oscillatory mTOR inhibition and Treg increase in kidney transplantation","volume":"182","author":"Sabbatini","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0015","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/TP.0000000000002495","article-title":"mTOR Inhibitor Everolimus in regulatory T cell expansion for clinical application in transplantation","volume":"103","author":"Gedaly","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0016","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1177\/0963689719872488","article-title":"Comparing the effects of the mTOR inhibitors azithromycin and rapamycin on in vitro expanded regulatory T cells","volume":"28","author":"Bergstr\u00f6m","year":"2019","journal-title":"Cell Transplant"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0017","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.celrep.2019.12.081","article-title":"Treg-cell-derived IL-35-coated extracellular vesicles promote infectious tolerance","volume":"30","author":"Sullivan","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0018","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1097\/TXD.0000000000000580","article-title":"Kinetics of alloantigen-specific regulatory CD4 T cell development and tissue distribution after donor-specific transfusion and costimulatory blockade","volume":"2","author":"Tomita","year":"2016","journal-title":"Transplant Direct"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0019","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3389\/fimmu.2016.00087","article-title":"Transplantation tolerance induction: cell therapies and their mechanisms","volume":"7","author":"Scalea","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0020","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.immuni.2009.03.019","article-title":"Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor","volume":"30","author":"Miyara","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107661","article-title":"CD45RA-CD25highCD127-CD4+ activated regulatory T cells are correlated with de novo donor-specific anti-HLA antibody formation after kidney transplantation in standard immunosuppression","volume":"97","author":"Tomita","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0022","article-title":"Reduced CD4","volume":"60","author":"Mirzakhani","year":"2020","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0023","article-title":"Immunological imprint on peripheral blood in kidney transplant recipients after two doses of SARS-CoV-2 mRNA vaccination in Japan","volume":"9","author":"Takiguchi","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.transproceed.2023.03.037_bib0024","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216300","article-title":"Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen-low dose tacrolimus with everolimus versus standard dose tacrolimus with mycophenolate mofetil","volume":"14","author":"Traitanon","year":"2019","journal-title":"PLoS One"}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113452300204X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113452300204X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T21:46:32Z","timestamp":1758577592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004113452300204X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S004113452300204X"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2023.03.037","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Mammalian Target of Rapamycin Inhibition on Activated Regulatory T-Cell Expansion in Kidney Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2023.03.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}